New Haven-based IsoPlexis Corporation has formed a scientific advisory board (SAB) to help guide the company’s strategic direction in novel areas of immunology and oncology.

“We are honored to add the expertise of Drs. Arnie Levine, Ross Levine, and Antoni Ribas, to the team, alongside current board members Dr. James Heath and Dr. Rong Fan,” said Sean Mackay, CEO of IsoPlexis. “The contribution of this distinguished group of leading academic and industry scientists and physicians is an endorsement of the enthusiasm for our innovative platform and its role in immune-mediated disease and therapeutics.”